surrogate endpoints

Oncology

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

News

Insmed is working with a bronchiectasis patient organisation on a real-world trial of Brinsupri, the first FDA-approved drug for the lung disorder.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.